Background. Lung transplantation (LTPL) is considered as a salvage therapeutic option in patients with end-stage lung disease. However, there is a lack of sufficient data on the use of LTPL in patients with acute respiratory distress syndrome (ARDS).
L ung transplantation (LTPL) is an effective lifesaving treatment for patients with irreversible end-stage lung disease, and extracorporeal membrane oxygenation (ECMO) therapy is used as a bridge to transplantation for these patients. 1 However, in cases of acute respiratory failure, LTPL is considered as an impractical measure due to the limited availability of donor organs and limited time for evaluation of the critically ill candidates. 2 Although ECMO therapy for acute respiratory distress syndrome (ARDS) has been shown to have survival benefit, 3, 4 survival to hospital discharge remains at only 58%. 5 Recently, advancements in rescue therapy and extracorporeal support have increased the possibility of performing LTPL in patients with acute respiratory failure. However, data and experience regarding LTPL in patients with refractory acute respiratory failure such as ARDS with refractory hypoxemia is still lacking. [6] [7] [8] Also, there is great uncertainty on deciding when transplantation can be used as a therapeutic option for patients with refractory acute lung disease without underlying lung disease. Thus, we evaluated the use of LTPL in ARDS that has developed in the absence of underlying lung disease. We compared the outcomes of ARDS patients who needed to undergo LTPL as a rescue therapy.
MATERIALS AND METHODS

Study Design
This retrospective study was conducted at Asan Medical Center, a tertiary referral center located in Seoul, Korea. Data were collected by reviewing medical records of the patients. This study was approved by the institutional review board of Asan Medical Center (study number: 2015-0743), and the need for informed consent was waived due to its retrospective nature.
Subjects
Patients who had ARDS with no underlying end-stage lung disease and were put on the waiting list of the Korean Network for Organ Sharing (KONOS) for lung transplant between October 2008 and October 2013 were included in this study. The patients fulfilled the Berlin definition of ARDS. 9 Indications for ECMO therapy and for the need of LTPL are provided in Appendix, SDC, http://links.lww.com/TP/B504.
Data Collection
Demographic and clinical data of the patients were collected, and data regarding ECMO and LTPL were also collected. Details are provided in Appendix, SDC, http://links. lww.com/TP/B504.
Statistical Analysis
The primary outcome was mortality before discharge from the hospital. The secondary outcome was survival time, which was defined as the number of days from hospital admission to death. Statistical analyses are provided in Appendix, SDC, http://links.lww.com/TP/B504.
RESULTS
Patient Characteristics
Three hundred five patients with severe ARDS were identified during the study period, and among them, 14 patients were listed for lung transplant due to ARDS without underlying end-stage lung disease (Table 1) . The mean age of the 14 patients was 39 ± 11 years and 8 (57%) were females. Accidental inhalation of humidifier disinfectant was the most common (50%) cause of ARDS in these 14 patients, which was from the cluster of lung injury associated with humidifier disinfectant that occurred in South Korea in 2011. 10 These patients showed rapid and progressive hypoxemic respiratory failure with diffuse bilateral lung infiltrations, and their clinical courses were so serious that half of patients underwent mechanical ventilation (MV) followed by ECMO therapy. Most of those patients were young and had no underlying disease or any other organ dysfunction; thus, they were considered as candidates for LTPL. Pneumonia was the second most common cause (29%) ( Table S1 , http://links.lww. com/TP/B504). Almost all patients had no underlying chronic disease except for 3 patients: 1 with controlled diabetes mellitus and hypertension, 1 with coronary arterial disease, status-post coronary artery bypass grafting with postoperative acute kidney injury (AKI) in the setting of acute respiratory failure, and 1 with a reopened atrial septal defect (ASD) 2 weeks ago, status postsurgical closure of ASD 10 years ago. Upon admission to our intensive care unit (ICU), the median the Acute Physiology and Chronic Health Evaluation II (APACHE II) score was 18, and the majority of patients required MV.
Clinical Course
During the course of ICU care, all patients received MV and 12 underwent ECMO. Decision making on LTPL was made after the patients had received MV for a mean of 16 days (interquartile range [IQR], 3-35) with or without ECMO support. LTPL was also considered for 2 patients who did not receive ECMO. One of these patients underwent surgical lung biopsy immediately after ICU admission for a definite diagnosis. His pathologic findings-destructive and obliterative bronchiolitis with bronchocentric fibrosis- were consistent with lung injury associated with humidifier disinfectant. Because all patients previously admitted to the ICU due to ARDS by humidifier disinfectant experienced rapid progressive deterioration, the patient was expected to have further rapid deterioration in his lung function. Considering that most of patients before him did not survive without LTPL with ECMO therapy, we decided that he would undergo LTPL even though his condition did not yet require a prompt ECMO therapy. The other patient who underwent LTPL without ECMO therapy had received coronary artery bypass graft (CABG) surgery due to myocardial infarction (MI) with severe left ventricular dysfunction. Postoperatively, he had suffered from pulmonary ARDS due to postoperative pneumonia. Despite his CABG, his heart function was severely impaired, and his lungs started to show bilateral fibrotic changes after ARDS and long-term MV and were unable to be weaned off MV for approximately 6 weeks. The patient needed to undergo cardiac transplantation and also was considered to undergo concomitant LTPL to be liberated from MV. At the time of KONOS listing, transthoracic echocardiography revealed that 13 patients (93%) had pulmonary hypertension: 6 patients with mild degree of pulmonary hypertension defined as estimated right ventricular systolic pressure of 35 to 45 mm Hg on echocardiography, 3 patients with moderate (46-60 mm Hg), and 4 patients with severe (more than 60 mm Hg) degree. At the time of KONOS listing, the patients on ECMO had severe hypoxemia with a median PaO 2 (P)/FiO 2 (F) ratio of 52 mm Hg (IQR, 44-80 mm Hg), and those on MV had a median P/F ratio of 108 mm Hg (IQR, 89-205 mm Hg). No other concomitant organ failures were found, with the exception of 1 patient who had AKI after his CABG surgery. The median the Sequential Organ Failure Assessment (SOFA) score of the patients at the time of listing was 8 (IQR, 7-10) ( Table 2) .
Outcomes According to LTPL Status
A total of 14 patients were placed on the KONOS waiting list. Among them, 9 patients underwent LTPL. There were no significant baseline differences between the 2 groups who received transplantation and those who did not (Appendix ,  Table S1 , http://links.lww.com/TP/B504). At the time of LTPL, patients still had low P/F ratios (median, 81; IQR, 52-120). The median SOFA score directly before LTPL was 9 (IQR, 7-10) ( Table 2 ). 
Of the 14 patients with ARDS, 9 patients underwent LTPL and 5 patients did not. Of the 9 patients who underwent LTPL, 8 patients survived, whereas only 1 patient survived among the 5 patients who did not undergo LTPL.
Of the 9 patients who underwent LTPL, 8 patients survived; in contrast, of the 5 patients who did not undergo LTPL, only 1 patient survived during their stay in the ICU ( Figure 1 , Table 3 ). The ICU and hospital mortality rates were 11% for the patients with LTPL, and 80% for the patients who did not undergo LTPL (P = 0.023). The median survival time of the patients with LTPL was significantly longer than in patients who did not undergo LTPL (1996 days [IQR, 872-2239] vs 49 days [IQR, ; P = 0.014) ( Table 3) .
Outcomes Compared With Historical ARDS Patients
A total of 596 ARDS patients were treated in our medical ICU between 2008 and 2013. Among them, 305 patients had severe ARDS according to the Berlin definition. Their 30-day, ICU and hospital mortality rate was 50%, 60%, and 66%, respectively. Among the 305 patients, 14 patients were listed for LTPL. When the 14 patients who were listed for lung transplant were compared with other patients who were treated for severe ARDS around the similar period without consideration for LTPL, their survival benefit was maintained (Table 4) . Compared with 14 patients with severe ARDS who failed weaning off of ECMO but were not listed for lung transplant, the 14 patients who were listed had a significantly lower mortality rate during long-term follow-up as well as short-term follow-up. Furthermore, the 14 patients who were listed for lung transplant showed significantly better outcomes than the unlisted 291 patients. Even though the latter had no other comorbidities including pulmonary disease, the former showed significant survival benefit for ICU, hospital, 30-day, 90-day, and 6-month mortalities.
Clinical Characteristics of Patients Undergoing LTPL
Of the 9 patients who underwent LTPL, 3 patients received heart-lung transplantation and 6 patients received bilateralsequential LTPL (Table 5 ). One of the 3 patients who underwent heart-lung transplantation had suffered from a recent MI, followed by fibrotic ARDS due to pneumonia contracted during ICU care. The patient had a severe post-MI left ventricular dysfunction for a period of 3 months, which resulted in the patient undergoing a heart-lung transplantation. Another patient that underwent a heartlung transplantation had a 10-year history of ASD closure; the patient recently underwent ASD creation due to newly developed pulmonary hypertension and was diagnosed with ARDS due to pneumonia contracted during postoperative care. The third patient that underwent a heart-lung transplantation had ARDS caused by inhalation of humidifier disinfectant; the patient did not have any underlying chronic disease and had received MV for a month without ECMO therapy before LTPL during ICU care. He was planned to receive bilateral-sequential LTPL immediately before operation; however, the patient developed severe pulmonary hypertension and right-sided heart failure at the onset of the surgery resulting in the patient requiring extracorporeal circulation during surgery. The transplant team therefore decided to perform a heart-lung transplantation instead of LTPL. Of the 6 patients with bilateral-sequential LTPL, 3 patients had ARDS due to humidifier disinfectant inhalation, and the additional 3 patients had ARDS due to pneumonia, acute interstitial pneumonia (AIP), and near drowning. The median time from ECMO to LTPL was 14 days (IQR, 10-27). Other times to LTPL are shown in Table 5 .
Outcomes of Patients Who Did Not Undergo LTPL
Five patients did not receive LTPL although they were listed for lung transplant. Only 1 of the 5 patients survived without LTPL. The surviving patient had ARDS caused by pneumonia and received ECMO therapy for 84 days. He was placed on the waiting list of KONOS on day 40 of ECMO therapy because his P/F ratio did not improve. However, 1 month after he was listed on KONOS, a slight improvement in his lung function was observed. An adequate donor was found 65 days after the commencement of ECMO, and the patient still required ECMO for adequate oxygenation; however, the patient was taken off the list for LTPL due to clinical improvement. His P/F ratio gradually improved, and he was discharged from ICU to general ward after 133 days. After an additional 38 days, he was discharged from the hospital. The other patients who did not undergo LTPL all died. Their cause of death and reason for not receiving LTPL are listed in Table 6 . These patients did not die because of progressive respiratory failure by ARDS, but rather due to sudden complications related with ECMO support, such as hypovolemic shock or sudden brain death secondary to suspected acute intracranial hemorrhage. They had maintained relatively stable status after the beginning of their ECMO and their deterioration had suddenly developed, even in 1 patient who developed multiorgan failure. Moreover, 3 patients had waited for transplant as long as 1 month after starting ECMO.
Post-LTPL Outcomes
All patients who received LTPL were followed up for a period of 64 months (IQR, 28-72). The median survival time of the patients after LTPL was 64 months (IQR, 28-72). The 1-month survival rate of the patients after LTPL was 100%, and their 3-month, 6-month, and 3-year survival rates were 89%, 89%, and 78%, respectively (Table 7 ). After LTPL, 2 patients died during the follow-up period. One patient who had received a heart-lung transplantation died of septic shock due to pneumonia 31 days after LTPL; this patient had undergone long-term MV care in the ICU before LTPL, and thus weaning from MV was difficult due to acquired muscle weakness. There was 1 patient among those who received LTPL who had a postgraft dysfunction immediately after LTPL, with a P/F ratio of 168 mm Hg (Grade 3). She had a preoperative severe pulmonary hypertension with RV dysfunction. Inhaled nitric oxide therapy was applied at a concentration of 25 ppm. During 72 hours after LTPL, she gradually recovered from postgraft dysfunction and was liberated from MV 19 days after receiving LTPL. She discharged from the hospital at 79 days after admission. However, since then, she had recurrent pneumonia due to stenosis of the right bronchus intermedius caused by acute rejection, which was confirmed by bronchoscopic biopsy. Finally, she died of pneumonia. The patient survived for a period of 249 days after LTPL. In contrast, the other 7 patients survived for at least 4 years with no significant complications. 
Pathological Findings of the Patients' Lung Biopsies and Explanted Lungs
Lung biopsies were conducted in 4 patients during the clinical course due to deterioration; 3 of these were performed as a surgical lung biopsy, and 1 was performed as a percutaneous needle biopsy. Destructive and obliterative bronchiolitis with peribronchial organizing diffuse alveolar damage (DAD) was found in all 4 patients. Epidemiological and experimental investigations in animal models revealed inhalation of humidifier disinfectant to be the cause of ARDS.
The majority of explanted lungs from patients undergoing LTPL showed lung fibrosis with DAD (Table 8 ). End-stage lung fibrosis with destructive and obstructive bronchiolitis was found in 4 patients who had inhaled humidifier disinfectant. End-stage lung fibrosis was found in the patient with near drowning, and a fibrotic phase of DAD was observed in the patient with AIP. Among the 3 patients with pneumonia, 2 had fibrotic changes and 1 had organizing DAD without lung fibrosis.
DISCUSSION
Our study demonstrates that patients with severe ARDS may benefit from LTPL as a final therapeutic option when conventional therapies are ineffective. We listed 14 ARDS patients for lung transplant. When oxygenation could not be maintained by MV, the majority of patients underwent ECMO therapy before LTPL. As a result, 9 patients received LTPL, and of these, 8 patients were discharged from the ICU and the hospital, whereas out of the 5 patients who did not undergo LTPL, 4 patients died mainly due to complications resulting from ECMO therapy. Only 1 patient survived severe ARDS after 3 months of ECMO therapy without LTPL.
In patients who underwent LTPL, the hospital mortality was 11%; in contrast, mortality of patients with severe ARDS has been reported to be approximately 45%. 9 A number of case reports and case series have demonstrated that ECMO may be a bridge therapy to LTPL in patients with acute respiratory failure along with chronic lung disease. 6, [11] [12] [13] [14] [15] [16] [17] Recently, there have been major technical advances in ECMO circuit 18 ; as a result, ECMO therapy as a bridge to LTPL has resulted in significant improvement of short-term survival. 19 In refractory ARDS without underlying lung disease, LTPL has been reported to be beneficial in patients with paraquat poisoning, [20] [21] [22] AIP, 14, 23 posttraumatic ARDS, 24,25 inhalation injury-related ARDS, 26 sepsis-induced ARDS, 27 pneumoniainduced ARDS, 6 and post-ARDS fibrosis with long-term MV. 28 As many of the afflicted patients were young, it was rather difficult for physicians to wait and observe the development of the patients' conditions, particularly when they did not have any prior lung disease and serious comorbidities during their clinical course. For these reasons, LTPL is regarded as the last rescue therapy.
Recently, LTPL was suggested as a rescue therapy in the management of refractory hypoxemia in ARDS. 2 Our study demonstrated a significant difference in hospital mortality in patients with severe ARDS after LTPL. Upon ICU admission, the patients who did not undergo LTPL showed lower P/F ratios and higher APACHE II scores. All these patients underwent ECMO therapy; at the time of listing on KONOS, the patients still had low P/F ratios and high SOFA scores. Although it was not statistically significant, this may be a defining factor between the 2 groups and raises a question whether they were more severely ill, and then developed complications that precluded them from receiving LTPL. However, their causes of death were either sudden complications or complicated infection related to ECMO therapy, which developed when they were stable under ECMO support. Whereas the median waiting time from listing to LTPL of patients who underwent LTPL was only 9 days, the waiting time from listing of the patients who could not receive LTPL was near 1 month except for 1 patient. Also, whereas the mean duration from ICU admission to LTPL of patients who received LTPL was 43 days, the mean duration from ICU admission to death of patients who did not receive LTPL was 38 days. This suggests that it is not true that patients who did not receive LTPL could not receive LTPL because their illness was too severe to undergo LTPL. For these reasons, we assert that patient not receiving LTPL were not at a disadvantage for receiving LTPL, even though their baseline P/F ratios and APACHE II scores were different. Thus, LTPL may have been effective for their survival if they had been able to undergo transplantation.
The most important and difficult problem that was faced in this study was the decision concerning the reversibility of lung function in patients with acute respiratory failure. Whenever LTPL was decided for each patient, intensive discussions were made on whether the patient's lung function was reversible. After getting listed on KONOS, the patients were carefully monitored to observe whether they would recover from their illness. Only 1 patient gradually recovered from severe ARDS within 3 months of ECMO therapy. After our experience with this case, we became more careful about our decisions regarding LTPL. The decision of reversibility for ARDS patients has aroused numerous arguments and is rather controversial. [29] [30] [31] In our study, most patients received MV for at least 2 weeks, but did not show any clinical improvement and required further intensive therapies. Their chest images persistently showed infiltrates of parenchyma throughout the whole lung or severely reduced lung compliances, which made us believe that they had developed irreversible lung parenchymal changes associated ARDS such as extensive fibrosis. Subsequent pathological examinations of the explanted or autopsied lungs revealed that most patients had end-stage lung fibrosis that was consistent with our clinical judgment. However, 2 patients did not demonstrate irreversible parenchymal changes in their explanted lungs. Both of them underwent heart-lung transplantation due to concomitant post-MI left ventricular dysfunction or pulmonary hypertension which significantly deteriorated after ASD creation. We concluded that the need for a heart transplantation outweighed that of LTPL in these patients.
In the setting of acute lung disease, the question of when and how to decide the timing of LTPL consideration remains unanswered. Lung biopsy may help in making the decision; however, it is difficult to perform lung biopsy in patients who have minimal lung function. Also, it is uncertain that whether lung biopsy could be representative of the status of the whole lung. The results of our current study suggest that for patients not showing significant improvement in their lung function even with maximal of medical support, the clinical decisions made on the basis of chest imaging or lung mechanics are of significant importance. In such case, LTPL might be the last therapeutic option for treating the acute refractory respiratory failure. The long-term outcome of ARDS patients who have undergone LTPL is currently unknown. Literature search results show that 17 ARDS patients have undergone LTPL. 6, 14, 20, 21, [23] [24] [25] [26] [27] [28] [32] [33] [34] Of those patients, 14 patients whose survival times were noted showed 2 different survival patterns-early mortality within 3 months (4 patients), and long-term survival between 1 and 5 years (10 patients). Our study population showed a considerable long-term survival rate of 78% over 4 years posttransplantation. According to the recent U.S. National Data between 2008 and 2015, 35 1-, 3-, and 5-year survival rates for lung transplant for recipients of ages 35 to 49 years were 89%, 74%, and 61%, respectively. The survival rates of our patients are not significantly different from those data, but slightly higher. Also, comparing with posttransplant 3-year (68%) and 5-year (52%) survival rates of patients with idiopathic pulmonary fibrosis, the survival rates of our patients do seem better. With regard to a recent report that described the outcomes of patients with ECMO as a bridge to LTPL, 36 patients supported with ECMO had higher perioperative mortality than patients without ECMO (19% vs 7%). However, an acceptable midterm survival was demonstrated, and no significant difference was found in the survival rates in patients with and without ECMO therapy at 1 year (74% vs 78%) and 3 years (65% vs 62%) after LTPL. In contrast, 7 patients in our study who underwent ECMO as a bridge to lung transplant showed not only better 30-day survival rate of 100% but also favorable 1-year and 3-year survivals of 86% and 86%, respectively. This result also suggest that long-term outcomes of LTPL bridged by ECMO therapy in cases of acute lung disease are not significantly different from or might even be better than those of LTPL in cases of conventional indications such as end-stage lung disease. Thus, LTPL may act as an additional therapeutic option in properly selected patients with severe refractory ARDS.
LIMITATIONS
This study has the following limitations. First, the study is retrospective in nature, and involves a small number of cases. Therefore, it may be vulnerable to inevitable selection bias when the LTPL candidates were chosen. We compared the mortality rates between the patients listed for LTPL and other patients who were treated for severe ARDS around the similar period. However, their baseline characteristics were very different from each other. Thus, we designed our study as a case series instead of case-control study. Second, the study was performed at a single center, which limits generalization of its findings and suggestions. Furthermore, inhalation of humidifier disinfectant was the major cause of ARDS in the patients in this study. Therefore, we cannot distinctly define these patients as true representatives of all patients with ARDS encompassing other causes. More data are needed to demonstrate the feasibility of LTPL as a salvage therapy for refractory severe ARDS in general.
CONCLUSIONS
Our study demonstrated the feasibility of LTPL as a final therapeutic option in ARDS patients. However, physicians should carefully select those who do not have any accompanying organ dysfunction or serious comorbidities, and concern for the reversibility of lung function should be anticipated as well. An appropriate selection of ARDS patients for LTPL may result in significant survival benefits.
